

Pharmaceuticals & Biotechnology


Source: Eikon Thomson Reuters

Market data

EPIC/TKR	GDR
Price (p)	36.4
12m High (p)	42.5
12m Low (p)	25.0
Shares (m)	18.9
Mkt Cap (£m)	6.9
EV (£m)	9.2
Free Float*	48%
Market	AIM

*As defined by AIM Rule 26

Description

Genedrive is a disruptive platform designed to bring the power of central laboratory molecular diagnostics to the point-of-care/near-patient setting, in a low-cost device offering fast and accurate results, initially for diagnosis of serious infectious diseases such as hepatitis.

Company information

CEO	David Budd
CFO	Matthew Fowler
Chairman	Ian Gilham
	+44 161 989 0245
	www.genedriveplc.com

Key shareholders

Directors	8.1%
Calculus	16.1%
M&G	13.0%
Odey	12.7%
Hargreave Hale	6.9%
River & Merc.	5.6%

Diary

Jul-18	Trading update
Oct-18	Finals

Analysts

Martin Hall	020 7194 7632	mh@hardmanandco.com
Dorothea Hill	020 7194 7626	dmh@hardmanandco.com
Grégoire Pavé	020 7194 7628	gp@hardmanandco.com

GENEDRIVE PLC

Preventing hearing loss in newborns

genedrive plc (GDR) is a commercial-stage company focused on point-of-care molecular diagnostics. Its Genedrive® molecular diagnostic testing platform is at the forefront of this technology, offering a rapid, low-cost, simple-to-use device with high sensitivity and specificity in infectious disease diagnosis. Rapid analysis of patient samples greatly aids clinical and public health decision-making, with field testing particularly important in emerging markets. GDR has been awarded a £550k grant from the UK's National Institute for Health Research (NIHR) to develop a diagnostic to prevent hearing loss resulting from adverse reactions to gentamicin.

- **Strategy:** Now that the Genedrive technology platform has received CE Marking, the new management team has completely re-focused the company onto the commercialisation pathway for diagnosis of infectious diseases, signing two important commercial agreements with Sysmex, a major global player.
- **Hearing loss in newborns:** There is a major unmet need in developed countries to prevent the adverse reactions that occur in a small minority of patients in the course of life-saving antibiotic treatment. Reactions can be severe, and lead to irreversible and complete hearing loss. Current testing technology is too slow.
- **NIHR grant:** As part of a collaboration with the NHS, GDR will develop a rapid diagnostic for mutations in the (human) mitochondrial gene, RNR1. It will run on the portable, point-of-care Genedrive technology device. Clinically actionable results will be available within the one hour required for treatment.
- **Risks:** The platform technology has been de-risked through the receipt of CE Mark for its first two assays (hepatitis C and tuberculosis). The main risk is commercial, given that it often takes time for new technologies to be adopted. However, partnering with major global and local players reduces this risk.
- **Investment summary:** Genedrive technology ticks all the boxes described for an 'ideal' *in vitro* diagnostic that satisfies the need for powerful molecular diagnostics outside the hospital setting. The hepatitis C market is a global opportunity, which is very large, even in developing countries. With strong partners being signed for different countries, such as the NHS in the UK, and evidence of early sales traction, there is, in our opinion, a valuation anomaly existing.

Financial summary and valuation

Year-end June (£000)	2015	2016	2017	2018E	2019E	2020E
Sales	4,517	5,063	5,785	4,869	3,447	4,826
Underlying EBIT	-3,858	-5,259	-4,812	-4,664	-3,681	-2,709
Reported EBIT	-4,040	-5,426	-7,292	-4,784	-3,837	-2,927
Underlying PBT	-3,242	-6,330	-5,007	-4,994	-4,146	-3,180
Statutory PBT	-3,424	-6,497	-7,487	-5,114	-4,302	-3,399
Underlying EPS (p)	-28.3	-54.6	-21.4	-21.5	-16.4	-10.1
Statutory EPS (p)	-30.1	-56.2	-34.9	-22.2	-17.1	-11.0
DPS (p)	0.0	0.0	0.0	0.0	0.0	0.0
Net (debt)/cash	903	-3,877	-70	-2,362	-5,175	-6,947
Capital increases	80	0	6,023	0	1,250	0
P/E (x)	-1.3	-0.7	-1.7	-1.7	-2.2	-3.6
EV/sales (x)	2.0	1.8	1.6	1.9	2.7	1.9

Source: Hardman & Co Research

Diagnostic to prevent hearing loss

Key features

- ▶ A £550k grant awarded to GDR by the NIHR for development of a genetic diagnostic test for prevention of antibiotic-related hearing loss in newborns.
- ▶ Two-year development and trial project in an NHS point-of-care (PoC) setting.
- ▶ Potentially accelerates GDR to high-income emergency care settings, expanding beyond the low- and middle-income markets targeted with its TB and HCV tests.
- ▶ Gentamicin reactions - significant unmet need worldwide, which is impacted by the restricted choice of antibiotics resulting from growing antibiotic resistance.

Gentamicin and hearing loss

Due to the genetic similarity of a mitochondrial gene (RNR1) variant to genetic sequences in bacteria, a small proportion of people experience toxicities that can lead to severe hearing loss when treated with aminoglycoside antibiotics, such as gentamicin. Gentamicin is routinely used in emergency treatment of severe bacterial infections, such as those causing sepsis, and particularly in newborn children, within an hour of admission to intensive care. Currently, detection of RNR1 variants in patients is carried out using standard laboratory tests; unfortunately, results cannot be delivered within the one-hour timeframe, and, therefore, some children experience life-altering reactions in the course of lifesaving gentamicin treatment.

Market potential

Around 90,000 babies are treated per year in the UK with gentamycin. The prevalence of the most common RNR1 variant associated with adverse gentamicin reactions (m.1555A>G) is around 0.2% in Caucasian populations, meaning that, on average, 18 babies could be affected each year in the UK alone. While routine screening of all newborns may not be practicable, a rapid PoC diagnosis of those infants clinically recommended for gentamicin treatment would be cost-effective.

The development programme

The UK's NIHR has awarded a £550k 'Invention to Innovation' grant to GDR for the two-year project, which is expected to begin immediately. Development of the new test is likely to be straightforward, with only slight modification of the chemistry needed for recognition of the new target gene. As with the TB and HCV tests, there will be minimal sample preparation required – a buccal swab will be all that is needed to run the test. The implementation phase of the project will involve more complexity, given that the device will need to be incorporated into existing NHS procedures and infrastructure; however, a strong collaboration has been formed with Professor William Newman at the Manchester University NHS Foundation Trust, and, therefore, it should not be unduly problematic. GDR's partners are expected to receive around the same amount of grant funding for their part in the project.

Impact on GDR

This programme, if successful, would set the stage for expansion to a very large European market. It is the first programme for GDR that involves a high-income country and, should the RNR1 test be successfully implemented at a national level in the UK, it would reduce significantly the company's risk profile. We anticipate strong growth in sales of the device and testing cartridges from around 2023, as full UK market penetration is achieved and the technology is adopted by European healthcare providers.

Summary financials

- ▶ **Services:** Grant-funded services include the NIHR grant, which is expected to be accrued in 2019 and 2020 with a weighting of around £0.4m in 2020. Grant-funded services include also the Innovate grants and income from the US DoD.
- ▶ **Discontinued ops.:** In May 2018, GDR completed the disposal of its services business for a £1.9m cash consideration, a small part of which will be deferred into 2019. Loss of income in June 2018 was around £0.3m.
- ▶ **RNR1 programme costs:** The costs have been accounted across 2019 and 2020 in proportion with the income, with no associated margin.
- ▶ **Forecasts:** Apart from the NIHR and other new grants, we have not altered our forecasts at this time (last updated for the disposal, in our June monthly publication). Our sales model of the RNR1 diagnostic impacts GDR from 2021.

Profit & Loss account						
Year-end June (£000)	2015	2016	2017	2018E	2019E	2020E
Profit & Loss						
Genedrive + services	814	1,906	2,619	2,049	3,447	4,826
Discontinued ops.	3,703	3,157	3,166	2,820	0	0
Sales	4,517	5,063	5,785	4,869	3,447	4,826
COGS	-3,933	-3,285	-2,998	-2,496	-911	-2,580
SG&A	-1,500	-2,201	-2,513	-2,337	-2,068	-1,158
R&D	-2,942	-4,836	-5,086	-4,700	-4,149	-3,796
Other income	0	0	0	0	0	0
Underlying EBIT	-3,858	-5,259	-4,812	-4,664	-3,681	-2,709
Share based costs	-182	-167	-101	-120	-156	-219
Statutory EBIT	-4,040	-5,426	-7,292	-4,784	-3,837	-2,927
Net financials	616	-1,071	-195	-330	-465	-472
Pre-tax profit	-3,242	-6,330	-5,007	-4,994	-4,146	-3,180
Exceptionals	0	0	0	0	0	0
Tax payable/credit	399	582	1,051	971	857	784
Underlying net income	-2,843	-5,748	-3,956	-4,022	-3,288	-2,396
Underlying Basic EPS (p)	-28.30	-54.58	-21.42	-21.5	-16.4	-10.1
Statutory Basic EPS (p)	-30.11	-56.16	-34.85	-22.2	-17.1	-11.0
Balance sheet						
Share capital	158	158	280	283	357	357
Reserves	9,387	3,595	3,161	-985	-3,253	-5,868
Provisions/liabilities	0	1,250	1,250	1,800	400	0
Debt	4,025	4,991	5,199	5,671	6,144	6,619
less: Cash	4,928	1,114	5,129	3,308	968	-328
Invested capital	8,612	8,880	4,761	3,461	2,679	1,437
Cashflow						
Underlying EBIT	-3,858	-5,259	-4,812	-4,664	-3,681	-2,709
Change in working capital	-1,122	44	1,308	-398	-440	134
Company op cashflow	-4,833	-4,192	-2,594	-4,068	-3,105	-1,559
Capital expenditure	-758	-164	-70	-100	-125	-156
Capital increase	80	0	6,023	0	1,250	0
Change in net debt	-3,335	-4,780	3,807	-2,104	-2,340	-1,297
Hardman FCF/share (p)	-35.0	-35.9	-9.9	-15.2	-11.8	-4.2

Notes

Disclaimer

Hardman & Co provides professional independent research services and all information used in the publication of this report has been compiled from publicly available sources that are believed to be reliable. However, no guarantee, warranty or representation, express or implied, can be given by Hardman & Co as to the accuracy, adequacy or completeness of the information contained in this research and they are not responsible for any errors or omissions or results obtained from use of such information. Neither Hardman & Co, nor any affiliates, officers, directors or employees accept any liability or responsibility in respect of the information which is subject to change without notice and may only be correct at the stated date of their issue, except in the case of gross negligence, fraud or wilful misconduct. In no event will Hardman & Co, its affiliates or any such parties be liable to you for any direct, special, indirect, consequential, incidental damages or any other damages of any kind even if Hardman & Co has been advised of the possibility thereof.

This research has been prepared purely for information purposes, and nothing in this report should be construed as an offer, or the solicitation of an offer, to buy or sell any security, product, service or investment. The research reflects the objective views of the analyst(s) named on the front page and does not constitute investment advice. However, the companies or legal entities covered in this research may pay us a fixed fee in order for this research to be made available. A full list of companies or legal entities that have paid us for coverage within the past 12 months can be viewed at <http://www.hardmanandco.com/legals/research-disclosures>. Hardman may provide other investment banking services to the companies or legal entities mentioned in this report.

Hardman & Co has a personal dealing policy which restricts staff and consultants' dealing in shares, bonds or other related instruments of companies or legal entities which pay Hardman & Co for any services, including research. No Hardman & Co staff, consultants or officers are employed or engaged by the companies or legal entities covered by this document in any capacity other than through Hardman & Co.

Hardman & Co does not buy or sell shares, either for their own account or for other parties and neither do they undertake investment business. We may provide investment banking services to corporate clients. Hardman & Co does not make recommendations. Accordingly, they do not publish records of their past recommendations. Where a Fair Value price is given in a research note, such as a DCF or peer comparison, this is the theoretical result of a study of a range of possible outcomes, and not a forecast of a likely share price. Hardman & Co may publish further notes on these securities, companies and legal entities but has no scheduled commitment and may cease to follow these securities, companies and legal entities without notice.

The information provided in this document is not intended for distribution to, or use by, any person or entity in any jurisdiction or country where such distribution or use would be contrary to law or regulation or which would subject Hardman & Co or its affiliates to any registration requirement within such jurisdiction or country.

Some or all alternative investments may not be suitable for certain investors. Investments in small and mid-cap corporations and foreign entities are speculative and involve a high degree of risk. An investor could lose all or a substantial amount of his or her investment. Investments may be leveraged and performance may be volatile; they may have high fees and expenses that reduce returns. Securities or legal entities mentioned in this document may not be suitable or appropriate for all investors. Where this document refers to a particular tax treatment, the tax treatment will depend on each investor's particular circumstances and may be subject to future change. Each investor's particular needs, investment objectives and financial situation were not taken into account in the preparation of this document and the material contained herein. Each investor must make his or her own independent decisions and obtain their own independent advice regarding any information, projects, securities, tax treatment or financial instruments mentioned herein. The fact that Hardman & Co has made available through this document various information constitutes neither a recommendation to enter into a particular transaction nor a representation that any financial instrument is suitable or appropriate for you. Each investor should consider whether an investment strategy of the purchase or sale of any product or security is appropriate for them in the light of their investment needs, objectives and financial circumstances.

This document constitutes a 'financial promotion' for the purposes of section 21 Financial Services and Markets Act 2000 (United Kingdom) ('FSMA') and accordingly has been approved by Capital Markets Strategy Ltd which is authorised and regulated by the Financial Conduct Authority (FCA).

No part of this document may be reproduced, stored in a retrieval system or transmitted in any form or by any means, mechanical, photocopying, recording or otherwise, without prior permission from Hardman & Co. By accepting this document, the recipient agrees to be bound by the limitations set out in this notice. This notice shall be governed and construed in accordance with English law. Hardman Research Ltd, trading as Hardman & Co, is an appointed representative of Capital Markets Strategy Ltd and is authorised and regulated by the FCA under registration number 600843. Hardman Research Ltd is registered at Companies House with number 8256259.

(Disclaimer Version 8 – Effective from August 2018)

Status of Hardman & Co's research under MiFID II

Some professional investors, who are subject to the new MiFID II rules from 3rd January, may be unclear about the status of Hardman & Co research and, specifically, whether it can be accepted without a commercial arrangement. Hardman & Co's research is paid for by the companies, legal entities and issuers about which we write and, as such, falls within the scope of 'minor non-monetary benefits', as defined in the Markets in Financial Instruments Directive II.

In particular, Article 12(3) of the Directive states: The following benefits shall qualify as acceptable minor non-monetary benefits only if they are: (b) 'written material from a third party that is commissioned and paid for by a corporate issuer or potential issuer to promote a new issuance by the company, or where the third party firm is contractually engaged and paid by the issuer to produce such material on an ongoing basis, provided that the relationship is clearly disclosed in the material and that the material is made available at the same time to any investment firms wishing to receive it or to the general public...'

The fact that Hardman & Co is commissioned to write the research is disclosed in the disclaimer, and the research is widely available.

The full detail is on page 26 of the full directive, which can be accessed here: <http://ec.europa.eu/finance/docs/level-2-measures/mifid-delegated-regulation-2016-2031.pdf>

In addition, it should be noted that MiFID II's main aim is to ensure transparency in the relationship between fund managers and brokers/suppliers, and eliminate what is termed 'inducement', whereby free research is provided to fund managers to encourage them to deal with the broker. Hardman & Co is not inducing the reader of our research to trade through us, since we do not deal in any security or legal entity.



research@hardmanandco.com

35 New Broad Street
London
EC2M 1NH

+44(0)20 7194 7622

www.hardmanandco.com